HK Stock Market Move | BAO PHARMA-B(02659) rose more than 10% in the early morning trading. The application for the market approval of KJ103 new drug was recently accepted by the National Medical Products Administration.

BAO PHARMA-B (02659) surged more than 10% in the morning session, rising 9.01% to HK$17.9 by the time of publication with a trading volume of HK$195.163 million. In terms of news, Baoji Pharmaceutical announced previously that its self-developed injectable drug KJ103 has had its market approval application accepted by the National Medical Products Administration, with it being included in the priority review process. The drug is intended for desensitization therapy for highly sensitized kidney transplant patients. KJ103 is the first IgG-degrading enzyme in China to submit an NDA and the first low immunogenicity IgG-degrading enzyme to complete phase III clinical trials globally, offering a potential better solution and more effective drug for highly sensitized kidney transplant therapy. China Post Securities released a research report stating that Baoji Pharmaceutical's differentiated product layout is gradually yielding results. Its unique subcutaneous drug delivery platform and synthetic biology platform have built solid technological barriers, continuously releasing value through diversified cooperation models. It was reported that Baoji Pharmaceutical's first product, long-acting follicle-stimulating hormone SJ02, was approved for market in August 2025, with the first batch of orders delivered in November, marking the company's official entry into the commercialization stage. The core product, recombinant human hyaluronidase KJ017, was approved on March 31, 2026.